Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 117Terminated 16Active not recruiting 15Unknown 11Withdrawn 9Recruiting 6Suspended 2Not yet recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Lung Diseases, Interstitial 1Immunoblastic Lymphadenopathy 1HTLV-I Infections 1Enteropathy-Associated T-Cell Lymphoma 1Congenital Abnormalities 1

Interventions

Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Antibodies, Monoclonal 2sargramostim 1prednylidene 1pembrolizumab 1glucarpidase 1deltacortene 1brincidofovir 1Specimen Handling 1Rituximab 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Methods 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunotherapy, Active 1Immunization, Passive 1Health Care Economics and Organizations 1Etoposide 1Drug Therapy 1Coal Tar 1Brentuximab Vedotin 1Biopsy 1Biomarkers 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Lymphoma × Prednisone × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡